Clinical Trial Update: Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and local tolerability of intranasal gel formulations of XF-73 for Staphylococcus aureus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Infection

Drugs mentioned

• XF-73

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Staphylococcal Infection | Phase 1 | Status: COMPLETED